A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With <i>ALK‐</i> Positive or <i>ROS1</i> ‐Positive Solid Tumors-Reference-Cited by-同舟云学术

A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐ Positive or ROS1 ‐Positive Solid Tumors

Published:2023-01-27 Issue:5 Volume:63 Page:583-592
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Hanley Michael J.¹^ORCID,D'Arcangelo Manolo²,Felip Enriqueta³,Garrido Pilar⁴,Zhu Jiaxi¹,Ye Meng¹,Vranceanu Florin¹,Gupta Neeraj¹^ORCID

Affiliation:

1. Takeda Development Center Americas, Inc. Lexington Massachusetts USA

2. AUSL Romagna Ravenna RA Italy

3. Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology Barcelona Spain

4. IRYCIS, Ramón y Cajal University Hospital Madrid Spain

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2198

Reference28 articles.

1. Anaplastic lymphoma kinase in human cancer

2. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

3. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

4. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

5. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer;Acta Pharmacologica Sinica;2024-03-04

2. Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor;Clinical Pharmacokinetics;2023-07-26